Onalespib, also known as AT-13387 or AT13387, is a novel drug candidate that has potential in cancer treatment. It is a small molecule inhibitor that selectively binds to heat shock protein 90 (Hsp90), a molecular chaperone that stabilizes various client proteins involved in signal transduction, cell cycle control, and apoptosis. The molecular formula of this compound is C29H36N6O3, and its molecular weight is 516.64 g/mol. The CAS number of this compound is 912999-49-6.
Top Ten Keywords:
Synonyms: AT-13387, AT13387, 912999-49-6
Health Benefits: Onalespib is a promising candidate for cancer treatment due to its ability to selectively inhibit Hsp90, a critical chaperone involved in signaling pathways that are often dysregulated in cancer cells. By inhibiting Hsp90, Onalespib destabilizes client proteins involved in these pathways, leading to apoptosis or cell death. Preclinical studies have shown significant antitumor activity in several cancer cell types, including lung, breast, pancreatic, and prostate cancers.
Potential Effects: Onalespib has been shown to have potent antitumor effects in preclinical studies, both as a single agent and in combination with other chemotherapeutic agents. Clinical trials evaluating the safety and efficacy of Onalespib in cancer treatment are ongoing. One of the main advantages of Onalespib is its specificity for Hsp90, which reduces the risk of off-target effects.
Product Mechanism: Onalespib works by selectively binding to Hsp90, a molecular chaperone that contributes to the stability and function of various client proteins involved in cancer cell growth, survival, and differentiation. Hsp90 plays a critical role in stabilizing signaling proteins, such as the RAF-MEK-ERK pathway, that are often overexpressed or activated in cancer cells. By inhibiting Hsp90, Onalespib disrupts this pathway and triggers apoptosis.
Safety: Onalespib has been well-tolerated in preclinical studies and clinical trials, with minimal adverse side effects reported. The most common side effects reported include diarrhea, fatigue, nausea, and vomiting. However, the safety and tolerability of Onalespib are still being evaluated in clinical studies.
Side Effects: Although Onalespib is generally well-tolerated, some side effects have been observed, including gastrointestinal distress, rash, and liver function abnormalities. Additionally, Onalespib may interact with other drugs that are metabolized by the same enzymes.
Dosing Information: The dosing regimen of Onalespib varies depending on the type of cancer being treated, the patient's body weight, and their overall health. The drug is administered orally, and the recommended dose ranges from 50 to 300 mg, depending on the indication.
Conclusion: Onalespib is a promising candidate for cancer treatment due to its high specificity for Hsp90, a critical chaperone involved in cancer cell growth and survival. Numerous preclinical and clinical studies have shown that Onalespib has potent antitumor effects, particularly when used in combination with other chemotherapeutic agents. The safety and tolerability of Onalespib are still being evaluated, but so far, the drug has been well-tolerated in clinical trials. As research into Onalespib and other Hsp90 inhibitors continues, the potential for targeted cancer therapy continues to grow
